LncRNA PWRN1 inhibits the progression of hepatocellular carcinoma by activating PKM2 activity
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.216620 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Mingming Fei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technol…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Postdoctoral Science Foundation, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is one of the most prevalent and leading causes of cancer-related mortality worldwide. Long non-coding RNAs (lncRNAs) have been demonstrated to play vital roles in cancer development and progression. The lncRNA PWRN1 (PWRN1), acts as a tumor suppressor factor, which is low expressed in some cancers. However, the molecular mechanisms underlying the effects of PWRN1, especially the regulatory relationship with RNA binding protein in HCC remain largely unknown. In the present study, we demonstrated that PWRN1 was significantly down-regulated in HCC and correlated with better prognosis; furthermore, gain-of-function experiments showed that PWRN1 inhibited the proliferation of HCC cells. We further found that PWRN1 up-regulated pyruvate kinase activity and thus hinders the proliferation of HCC in vitro and in vivo. Mechanistically, pyruvate kinase M2 (PKM2) was bound to it and maintained the high activity state of PKM2, thereby hindering PKM2 from entering the nucleus in the form of low-activity dimers, reducing the expression of c-Myc downstream gene LDHA, leading to a decrease in lactate levels, and inhibiting the growth of tumor cells. In addition, PWRN1 was found to inhibit aerobic glycolysis. Finally, TEPP-46, a pyruvate kinase activator, appeared to inhibit HCC proliferation by maintaining tetramer stability and increasing pyruvate kinase activity. Taken together, our results provide new insights into the biology hindering HCC proliferation and indicate that PWRN1 in combination with PKM2 activators might represent a novel therapeutic target for HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui Province Key Laboratory of Hepatopancreatobiliary…
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui Province Key Laboratory of Hepatopancreatobilia…
Förderung
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Natural Science Foundation of Anhui Province
Zitieren
APA
Fei, M., Li, X., Liang, S., Zhou, S., Wu, H., Sun, L., Liu, Y., Hu, Q., Liu, L., & Wang, J. (2024). LncRNA PWRN1 inhibits the progression of hepatocellular carcinoma by activating PKM2 activity. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216620
Vancouver
Fei M, Li X, Liang S, Zhou S, Wu H, Sun L, et al. LncRNA PWRN1 inhibits the progression of hepatocellular carcinoma by activating PKM2 activity. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216620
BibTeX
@article{Fei2024,
author = {Fei, Mingming and Li, Xianying and Liang, Shuhang and Zhou, Shuo and Wu, Huihui and Sun, Linmao and Liu, Yao and Hu, Qingsong and Liu, Lianxin and Wang, Jiabei},
title = {LncRNA PWRN1 inhibits the progression of hepatocellular carcinoma by activating PKM2 activity},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.216620}
}
EUVIMED